Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

CureVac pulls its COVID-19 vaccine from EMA approval process

by Megha Satyanarayana
October 15, 2021 | A version of this story appeared in Volume 99, Issue 38

 

CureVac has pulled CVnCoV, its COVID-19 vaccine candidate, from the European Medicines Agency’s approval process. The company had submitted most preclinical data as part of the EMA’s rolling review process, intended to speed up approvals. CureVac says it will focus on its next-generation COVID-19 vaccine. EMA officials had raised questions about CVnCoV’s quality and efficacy.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.